Human Pharmaceuticals segment

Eli Lilly & Co.’s (LLY) Human Pharmaceuticals business reported revenues of ~$5.6 billion during the second quarter. This represents 10.0% YoY (year-over-year) revenue growth, compared to the second quarter of 2017.

This revenue growth was driven by a 9.0% increase in volume and a 2.0% positive impact of foreign exchange, partially offset by a marginal decrease due to prices. The chart below compares the revenues of the endocrine franchise’s key products since the first quarter of 2017.

Eli Lilly’s Q2 2018 Earnings: Human Pharmaceuticals Business

Endocrine products

Eli Lilly’s (LLY) endocrine products portfolio includes Humalog, Humulin, Basaglar, Trulicity, Jardiance, Trajenta, and Forteo. During the second quarter, Humalog, Basaglar, Jardiance, and Trulicity reported revenue growth. However, sales of Humulin and Forteo declined, and Trajenta reported nearly flat revenues during the quarter. The company’s endocrine products also include Glucagon, Humatrope, Actos, and Humapen.


Humalog products, which are mealtime insulin products, reported 13.0% YoY revenue growth to $769.8 million during the second quarter, compared to ~$678.4 million during the second quarter of 2017. This revenue increase was driven by 19.0% growth in its US sales to $464.5 million due to higher realized prices. This increase was also due to 6.0% growth in international sales to $305.2 million during the second quarter.


Humulin products, which are concentrated insulin products, reported revenues of $346.0 million during the second quarter. This represents a 3.0% decrease in YoY revenues compared to the second quarter of 2017. This decline was driven by an 18.0% decrease in international sales and partially offset by a 5.0% increase in its US sales during the quarter.


Forteo, an osteoporosis drug, reported revenues of ~$434.5 million during the second quarter. This represents a 3.0% YoY revenue decrease, compared to ~$446.7 million during the second quarter of 2017. The decline in Forteo’s revenues was driven by a 10.0% decrease in its US sales, which was partially offset by 7.0% growth in its international sales during the quarter.

Later in this series, we’ll discuss the performance of Basaglar, Jardiance, Trulicity, and other new drugs in Eli Lilly’s portfolio.

The Invesco Dynamic Pharmaceuticals ETF (PJP) holds 5.2% in Eli Lilly (LLY), 4.9% in Merck & Co. (MRK), 4.8% in Pfizer (PFE), and 4.1% in AbbVie (ABBV).

Latest articles

20 Jun

Will Refiners’ Earnings Plunge in 2019?

WRITTEN BY Maitali Ramkumar

Wall Street analysts expect refining firms' earnings to fall in 2019. Delek US Holdings (DK) and Valero Energy’s (VLO) earnings are estimated to fall less than 10% in 2019. However, the EPS of Marathon Petroleum (MPC), HollyFrontier (HFC), and Phillips 66 (PSX) are expected to fall 20%–40% this year.

After remaining tepid for the first four months of the year, gold prices have taken off in a big way. The initial impetus was provided by a tweet made by President Donald Trump on May 5, which revived trade tensions in a big way.

20 Jun

How Are Charter’s Revenues Trending in 2019?

WRITTEN BY Ambrish Shah

In the first quarter, Charter Communications (CHTR) reported total revenues of $11.2 billion—a rise of 5.2% year-over-year and $7 million ahead of the consensus estimate.

This morning before the market opened, Tesla (TSLA) was trading on a negative note despite a sharp rise in index futures. As of 9:10 AM ET, Tesla stock had fallen 1.2% in the pre-market session to $234.74 after Goldman Sachs cut the target price on the company by about 21%.

The US-China trade war has already given a scare to Apple’s (AAPL) investors vis-à-vis the possibility of a 25% tariff on Apple goods being imported from its Chinese facilities. As a result, Apple might be considering shifting its plants out of China.

Yesterday, Greenlane Holdings (GNLN) fell a whopping 17.1%. The stock has now fallen 28% this month, and it hit its all-time low yesterday. Greenlane Holdings listed in April and priced its IPO at $17 per share. However, since the stock surged more than 25% after its listing, it has been a sorry story for Greenlane Holdings investors.